[go: up one dir, main page]

AU2002358650A1 - Known and novel 4,5-dihydro-imidazo(4,5,1-ij)quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors - Google Patents

Known and novel 4,5-dihydro-imidazo(4,5,1-ij)quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors

Info

Publication number
AU2002358650A1
AU2002358650A1 AU2002358650A AU2002358650A AU2002358650A1 AU 2002358650 A1 AU2002358650 A1 AU 2002358650A1 AU 2002358650 A AU2002358650 A AU 2002358650A AU 2002358650 A AU2002358650 A AU 2002358650A AU 2002358650 A1 AU2002358650 A1 AU 2002358650A1
Authority
AU
Australia
Prior art keywords
quinolin
adp
imidazo
ribose
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002358650A
Inventor
Rainer Boer
Frank Dullweber
Thomas Wagner
Steffen Weinbrenner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Altana Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma AG filed Critical Altana Pharma AG
Publication of AU2002358650A1 publication Critical patent/AU2002358650A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002358650A 2001-12-14 2002-12-10 Known and novel 4,5-dihydro-imidazo(4,5,1-ij)quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors Abandoned AU2002358650A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP01000754 2001-12-14
EP01000754.0 2001-12-14
EP02012703 2002-06-07
EP02012703.1 2002-06-07
PCT/EP2002/013973 WO2003051879A1 (en) 2001-12-14 2002-12-10 Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors

Publications (1)

Publication Number Publication Date
AU2002358650A1 true AU2002358650A1 (en) 2003-06-30

Family

ID=26076431

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002358650A Abandoned AU2002358650A1 (en) 2001-12-14 2002-12-10 Known and novel 4,5-dihydro-imidazo(4,5,1-ij)quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors

Country Status (2)

Country Link
AU (1) AU2002358650A1 (en)
WO (1) WO2003051879A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
JP4500161B2 (en) 2002-04-30 2010-07-14 クドス ファーマシューティカルズ リミテッド Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
AU2004294790B2 (en) 2003-12-01 2010-03-11 Kudos Pharmaceuticals Limited DNA damage repair inhibitors for treatment of cancer
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
GB0716532D0 (en) 2007-08-24 2007-10-03 Angeletti P Ist Richerche Bio Therapeutic compounds
JP2010539149A (en) 2007-09-14 2010-12-16 アストラゼネカ アクチボラグ Phthalazinone derivatives
AR070221A1 (en) 2008-01-23 2010-03-25 Astrazeneca Ab DERIVATIVES OF FTALAZINONA POLYMERASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES OF THE SAME TO PREVENT AND / OR TREAT CANCERIGENE TUMORS, ISCHEMICAL INJURIES AND OTHER ASSOCIATED DISEASES.
PT2346495T (en) 2008-10-07 2016-11-11 Astrazeneca Uk Ltd Pharmaceutical formulation 514
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
GB201220157D0 (en) 2012-11-08 2012-12-26 Selvita Sa Substitute tricyclic benzimidazoles as kinase inhibitors
PT3325623T (en) 2015-07-23 2019-09-04 Inst Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
US20200129476A1 (en) 2017-04-28 2020-04-30 Akribes Biomedical Gmbh PARP Inhibitor in Combination with a Glucocorticoid and/or Ascorbic Acid and/or a Protein Growth Factor for the Treatment of Impaired Wound Healing
AU2019235337A1 (en) 2018-03-13 2020-08-27 Centre National De La Recherche Scientifique A Dbait molecule against acquired resistance in the treatment of cancer
GB201913030D0 (en) 2019-09-10 2019-10-23 Francis Crick Institute Ltd Treatment of hr deficient cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN121398822A (en) 2023-06-21 2026-01-23 四方生物科学有限公司 Combinations comprising deoxycytidine derivatives and PARP inhibitors for use in methods of treating cancers with normal heart rate function.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2899757B2 (en) * 1989-06-26 1999-06-02 持田製薬株式会社 Dihydroimidazoquinolinone oxime sulfonic acid derivative
EP0638570A4 (en) * 1992-04-27 1995-04-12 Mochida Pharm Co Ltd Tricyclic compound having antiallergic effect.
EP1077946A1 (en) * 1998-05-15 2001-02-28 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
KR100632079B1 (en) * 1999-01-11 2006-10-04 아구론 파마슈티컬스, 인크. Tricyclic Inhibitors of Poly (ADP-Ribose) Polymerase
ECSP003637A (en) * 1999-08-31 2002-03-25 Agouron Pharma TRICYCLE POLY INHIBITORS (ADP-RIBOSA) POLYMERASES

Also Published As

Publication number Publication date
WO2003051879A8 (en) 2003-11-27
WO2003051879A1 (en) 2003-06-26

Similar Documents

Publication Publication Date Title
AU2002358650A1 (en) Known and novel 4,5-dihydro-imidazo(4,5,1-ij)quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
AU2002361992A1 (en) 1,4-dihydro-1,4-diphenylpyridine derivatives
EP1443925B8 (en) Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
AU2002229976A1 (en) Imidazopyridines
AU2002317910A1 (en) Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof
AU2002365147A1 (en) Switchable surfaces
AU2002222293A1 (en) Pyrazolo(3,4-c)pyridines as gsk-3 inhibitors
IL175756A0 (en) 7-phenylalkyl substituted 2-quinolinones and 2 quinoxalinones as poly (adp-ribose) polymerase inhibitors
AU2002227985A1 (en) Pyrrolo (2.1-a) dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors
AU2002221753A1 (en) Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same
AU2002251149A1 (en) Fibre-enriched beverages
AU2002355284A1 (en) Direct-fed microbial
AU2001293214A1 (en) Heatsink retainer
AU2001229463A1 (en) Pathogen-reducing systems, compositions, articles and methods employing ozone
AU2003293886A1 (en) (1,7)naphthyridines as pde4 inhibitors
AU2001286188A1 (en) Tricyclic heterocyclic compound, process for producing the same, and use thereof
AU2003274993A1 (en) Pyrrolo(1,2-b)pyridazine compounds and their uses
AU2002356624A1 (en) Ptp10d, tec and edtp involved in triglycerid-metabolism
AU2002365643A1 (en) Substituted aryl-cycloalkanes, and use thereof as anticancer agents
AU2002229395A1 (en) Beverage
AU2002238981A1 (en) Tricyclic heterocyclic compound, process for producing the same, and use
HK1079192A (en) Pyrazolo(3,4-b)pyridine compounds, and their use as phosphodiesterase inhibitors
AU2002355340A1 (en) 3-substituted pyrrolo (2.1-a) isoquinoline derivatives
AU2002326524A1 (en) 3-substituted pyrrolo(2.1-a)isoquinoline derivatives
AU2002244960A1 (en) Polyester block copolymer composition

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase